Abstract 882P
Background
While strong evidence indicates quitting smoking reduces the risk of developing head and neck cancer (HNC), it remains unclear whether patients who smoke could still benefit from quitting after HNC diagnosis. We investigated the impact of postdiagnosis smoking cessation on the survival of patients with HNC who smoked at diagnosis.
Methods
This prospective study included 1,298 participants who were diagnosed with HNC in the United Kingdom (Head and Neck 5000 study, recruitment: 2011-2014), and 4 countries in Latin America (Brazil, Argentina, Uruguay, and Colombia - INTERCHANGE study, recruitment: 2011-2017) who actively smoked at diagnosis. Participants have been actively followed since their diagnosis to collect regular information on their smoking behavior and disease status. Overall survival was evaluated using extended Kaplan-Meier curves and time-dependent Cox proportional hazards regression models.
Results
During the follow-up, 442 participants (34%) reported quitting smoking, and 571 deaths were recorded. Median survival time was 17 months higher when patients quit vs. continued smoking (median survival time = 6.6 vs. 5.2 years, p<0.001). At 5-years, the survival rate was significantly higher when patients quit vs. continued smoking (61.0% vs. 50.6%, p<0.001). After accounting for the quitting time and adjusting for potential confounders, quitting smoking was associated with 33% lower risk of death compared to continued smoking (HR=0.67, 95%CI=0.56-0.81). Stratified analyses revealed consistent survival benefits associated with quitting smoking among all patient subgroups, including those who reported mild-moderate vs. heavy smoking, and patients who were diagnosed with earlier vs. later-stage tumors. The benefits of quitting smoking were also evident across various HNC subtypes.
Conclusions
Quitting smoking after HNC diagnosis may significantly reduce the risk of death and improve survival among patients who smoke. These findings underscore the importance of post-diagnosis smoking cessation interventions as part of comprehensive cancer care for HNC patients.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
751P - Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
Presenter: Carol Aghajanian
Session: Poster session 02
752P - Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival
Presenter: Tibor Zwimpfer
Session: Poster session 02
753P - Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trial
Presenter: Felix Blanc-Durand
Session: Poster session 02
754P - Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
Presenter: Ronnie Shapira-Frommer
Session: Poster session 02
755P - Beyond HRD status: Unraveling genetic variants impacting PARP inhibitor sensitivity in advanced ovarian cancer
Presenter: Maj Kamille Kjeldsen
Session: Poster session 02
756P - Final analysis of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
Presenter: Junsik Park
Session: Poster session 02
757P - Sustained long-term responders to niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): A subanalysis of the GEICO-88R study
Presenter: Juan Cueva Banuelos
Session: Poster session 02
758P - Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients
Presenter: Emese Zsiros
Session: Poster session 02
759P - JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies
Presenter: Qunxian Rao
Session: Poster session 02
760P - Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): An open, prospective, single arm, phase II trial
Presenter: Jie Tang
Session: Poster session 02